Xilio Therapeutics (NASDAQ:XLO) Posts Earnings Results, Beats Estimates By $0.64 EPS

Xilio Therapeutics (NASDAQ:XLO) released its quarterly earnings results on Tuesday. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.64, FiscalAI reports. Xilio Therapeutics had a negative return on equity of 71.99% and a negative net margin of 34.06%. The firm had revenue of $9.98 million for the quarter, compared to analyst estimates of $4.92 million.

Xilio Therapeutics Stock Down 1.0%

Shares of NASDAQ XLO traded down $0.09 during trading on Tuesday, hitting $8.91. 1,707 shares of the company traded hands, compared to its average volume of 32,398. Xilio Therapeutics has a 1 year low of $6.47 and a 1 year high of $11.30. The company has a 50-day moving average price of $8.75 and a 200-day moving average price of $8.50. The firm has a market capitalization of $58.63 million, a P/E ratio of -5.43 and a beta of -0.13.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Zacks Research upgraded shares of Xilio Therapeutics to a “hold” rating in a research report on Thursday, October 22nd. Raymond James Financial initiated coverage on Xilio Therapeutics in a report on Wednesday, October 21st. They issued an “outperform” rating and a $16.00 price target on the stock. Finally, Weiss Ratings upgraded Xilio Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Xilio Therapeutics has an average rating of “Hold” and a consensus target price of $16.00.

About Xilio Therapeutics

Xilio Therapeutics, Inc is a clinical-stage biotechnology company focused on developing tumor-activated immunotherapies for cancer. The company’s technology is designed to keep powerful immune-modulating medicines inactive in healthy tissue and activate them preferentially within the tumor microenvironment, with the goal of improving antitumor activity while reducing systemic side effects.

Xilio’s research and development programs have included engineered cytokines and immune checkpoint therapies, including tumor-activated versions of interleukin-2, interleukin-12 and CTLA-4-directed treatments.